Cargando…
Baricitinib with cyclosporine eliminates acute graft rejection in fully mismatched skin and heart transplant models
Solid organ transplant represents a potentially lifesaving procedure for patients suffering from end-stage heart, lung, liver, and kidney failure. However, rejection remains a significant source of morbidity and immunosuppressive medications have significant toxicities. Janus kinase (JAK) inhibitors...
Autores principales: | Abboud, Ramzi, Kim, Sena, Staser, Karl, Jayasinghe, Reyka G., Lim, Sora, Amatya, Parmeshwar, Frye, C. Corbin, Kopecky, Benjamin, Ritchey, Julie, Gao, Feng, Lavine, Kory, Kreisel, Daniel, DiPersio, John F., Choi, Jaebok |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10511772/ https://www.ncbi.nlm.nih.gov/pubmed/37744381 http://dx.doi.org/10.3389/fimmu.2023.1264496 |
Ejemplares similares
-
Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host disease
por: Choi, Jaebok, et al.
Publicado: (2018) -
Insights into the role of the JAK/STAT signaling pathway in graft-versus-host disease
por: Abboud, Ramzi, et al.
Publicado: (2020) -
Selective targeting of histone modification fails to prevent graft versus host disease after hematopoietic cell transplantation
por: Alahmari, Bader, et al.
Publicado: (2018) -
Pharmacologic Blockade of JAK1/JAK2 Reduces GvHD and Preserves the Graft-Versus-Leukemia Effect
por: Choi, Jaebok, et al.
Publicado: (2014) -
A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activity
por: Kim, Miriam Y., et al.
Publicado: (2022)